GSH + NAC: A Second Receipt, Not a Bonus
Mechanism poetry against the file — the pick-one default held, the deliberate both-doors buyer respected, and 'more pathways' priced as the marketing arithmetic it is.
At a glance
- Permitted, thin: no interaction — and no trial tested the pair either
- The redundancy truth: two doors, one pool — a second receipt, not a synergy
- The default: pick one route, run it on its clock, review at 12 weeks
- The knowing exception: a deliberate both-doors protocol, budgeted and owned
Why this stack keeps getting sold — and what the file actually holds
The GSH+NAC pairing is one of the aisle's most-marketed stacks, and the pitch writes itself: supply the precursor and the finished molecule, cover both pathways, comprehensive support — mechanism poetry that this page audits against the file: no trial has tested the combination against either route alone; the supporting evidence for each door was earned separately (oral GSH's six-month stores trial on the finished molecule — that finding; NAC's clinical pedigree and precursor logic — its honest card); and the pool being fed is singular — cysteine availability and direct repletion are two entrances to one reservoir, which makes the stack's true description redundancy with a second receipt rather than synergy with a bonus (the dose-level page where the two-doors framing lives). 'More pathways = better' is marketing arithmetic; the repletion model rewards consistency at one door, not tickets at both.
The costs the stack quietly doubles
What running both actually purchases, itemised: money — two products at £20-30 each monthly is £45-55/month feeding one pool, against ~77p/day feeding it once; attribution — the 12-week review's single question (did this line earn its place?) becomes unanswerable with two simultaneous inputs: whatever the stores did, neither bottle can claim it, and whatever a stomach objected to, neither can be cleared (the diagnostic that depends on isolation, the same logic at the formula level); and admin — the pharmacist minute lengthens honestly with each active on the list, NAC carrying its own notes worth checking (the routing). None of these is a safety alarm — label doses of both coexist without documented conflict — they're the quiet costs the stack's marketing never itemises, which is precisely this page's job.
Futuro Labs Glutathione
£22.99 for 30-day supply · 77p per day
Pros
- 500mg reduced glutathione (GSH) per serving — the active form
- UK manufactured under GMP certification
- Single-ingredient, vegan, no fillers
- Independently lab tested — microbiology and heavy metals
- ~77p per day vs £1.20-1.80/day for liposomal formats
Cons
- Capsule format — no liposomal delivery system
- Newer brand versus heritage names like Solgar
Available from: Amazon UK — £22.99
The default, the exception, and the close
The cluster's standing verdict, applied: pick one door — evidence-first buyers take the measured route (Futuro Labs Glutathione: 500mg reduced glutathione daily, the trial-matched finished molecule, single-ingredient, independently tested, £22.99/30 days at ~77p — the record); precursor-logic buyers take NAC knowingly with its inferential gap owned — run it properly on the shared clock (8-12 weeks minimum, 3-6 months full curve — the timeline), and let the 12-week review adjudicate one clean verdict (the review). The knowing exception, printed rather than pretended away: a deliberate both-doors protocol — budgeted, staggered at the start for baseline attribution, each rationale owned — is a defensible choice for the buyer who wants the redundancy and can afford the second receipt; this page just refuses to sell it as synergy. Constants as ever: protein feeds the cysteine pathway before any capsule does (the hierarchy), gates always — pregnancy/breastfeeding → medical advice; prescription medication → the pharmacist minute both actives lengthen. GSH and NAC together, answered: permitted, thin, and mostly a second ticket to a show one door already covers.
Frequently asked questions
Can you take glutathione and NAC together?
You can — no interaction concern at label doses — but this page exists to say the honest quiet part: the case is thin. Both routes feed the same pool (NAC as cysteine precursor, GSH as finished molecule), every supporting trial tested each alone, and running both mostly doubles cost while wrecking the attribution your 12-week review depends on. The cluster default: pick one door, run it properly.
Is there any synergy between them?
No trial demonstrates it: the synergy story is pure mechanism speculation (precursor supply plus finished molecule), and stacking two inputs to one pool isn't synergy — it's redundancy with a second receipt. The knowing exception exists (a deliberate, budgeted, both-doors protocol run with open eyes), but 'more pathways = better' is marketing arithmetic, not evidence.
If I had to pick one, which?
The dose-level comparison page runs this in full: oral GSH's file holds the direct six-month stores trial (the finished molecule, measured repleting); NAC's supplement case is inferential (real clinical pedigree in medicine, precursor logic for daily use). Evidence-first buyers take the measured door; precursor-logic buyers take NAC knowingly.